BIOSEEK PLC 
By
Asterand plc ("Asterand" or the "Company" - LSE: ATD)
announces today that, further to the announcement on 23
September 2011, it has received notification from the
National Cancer Institute ("NCI") that it will grant the
Company a no cost contract extension to 30 September 2014 for
The Cancer Genome Atlas contract ("TCGA"). This extension
will allow Asterand to realise unexpended funds for the
initial $5.4m contract beyond the original expiration date of
23 February 2012.
Contacts:
Jack Davis, Chairman and Interim Chief Executive Officer Tel:
+ 44 (0) 1763 211 600 / + 1 (313) 263-0960
Alan Fishman, Interim Chief Financial Officer As above
Lisa Baderoon / Mark Court / Isabel Podda Tel: +44 (0) 20 7466 5000
Daniel Stewart & Company plc
Antony Legge Tel: +44 (0) 20 7776 6550
Martin Lampshire
Asterand plc is a leading supplier of high quality human
tissue and tissue-based services. Our comprehensive approach
to human tissue and research services offers pharmaceutical,
biotech and diagnostic companies the unique opportunity to
have one company meet all of their human biomaterial needs
along the continuum of drug discovery and development. Our
mission is to accelerate target discovery and compound
validation and enable pharmaceutical and biotechnology
companies to take safer and more effective drugs into the
market. For more information about Asterand, go to www.asterand.com
- 1 -
